Redeye is positive on Senzime’s new contract with an Ivy League US hospital.
Prostatypes USA-studie har nyligen presenterats i en vetenskaplig tidskrift.
Timing of project revenue recognition is set to boost Q4 figures.
Cicor is an electronics manufacturing services (EMS) company with ~60 years of history, and we view ...
Seafire saw increasing stability during 2025, driven by internal efficiency measures and recovering ...
Redeye gives an initial take on the news that IRLAB has entered into a collaboration with Biomia reg...
Redeye initiates coverage of Guldbrev, the market-leading digital gold buyer in Sweden.
* Q4'25 numbers due on 10 February at 07:45 CET * Expect new targets on the reporting day, more info...
Redeye provides a quick comment on Cheffelo’s reverse profit warning for Q4 2025, released earlier t...
This morning SyntheticMR announced preliminary Q4 figures amid the ongoing rights issue.
Redeye expects to make mixed near-term estimate changes based on GomSpace's guidance announced this ...
* Q4 results due on Thursday, 5 February * Estimates up 2-4% organically, but neutralised by FX * Ma...
Redeye was surprised by Enviro’s press release on Friday evening announcing that Fredrik Emilson is ...
NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming tha...
OXE Marine published preliminary sales figures for Q4 which were significantly lower than we expecte...
Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 Januar...
Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financ...
The public release of Xspray’s CRL on openFDA yesterday triggered a double-digit intraday decline in...
Redeye presents a preview of Enea’s Q4 2025 report, due on 30 January 2026.
* Q4e: 4% organic sales growth, 11% adj. EBITA margin * We cut estimates on the downgraded outlook *...